Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer

Studies in infant ADA-Deficient mice and rhesus monkeys

Denise Carbonaro Sarracino, Alice F Tarantal, Charles C Lee, Michele Martinez, Xiangyang Jin, Xiaoyan Wang, Cinnamon L. Hardee, Sabine Geiger, Christoph A. Kahl, Donald B. Kohn

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Systemic delivery of a lentiviral vector carrying a therapeutic gene represents a new treatment for monogenic disease. Previously, we have shown that transfer of the adenosine deaminase (ADA) cDNA in vivo rescues the lethal phenotype and reconstitutes immune function in ADA-deficient mice. In order to translate this approach to ADA-deficient severe combined immune deficiency patients, neonatal ADA-deficient mice and newborn rhesus monkeys were treated with species-matched and mismatched vectors and pseudotypes. We compared gene delivery by the HIV-1-based vector to murine γ-retroviral vectors pseudotyped with vesicular stomatitis virus-glycoprotein or murine retroviral envelopes in ADA-deficient mice. The vesicular stomatitis virus-glycoprotein pseudotyped lentiviral vectors had the highest titer and resulted in the highest vector copy number in multiple tissues, particularly liver and lung. In monkeys, HIV-1 or simian immunodeficiency virus vectors resulted in similar biodistribution in most tissues including bone marrow, spleen, liver, and lung. Simian immunodeficiency virus pseudotyped with the gibbon ape leukemia virus envelope produced 10- to 30-fold lower titers than the vesicular stomatitis virus-glycoprotein pseudotype, but had a similar tissue biodistribution and similar copy number in blood cells. The relative copy numbers achieved in mice and monkeys were similar when adjusted to the administered dose per kg. These results suggest that this approach can be scaled-up to clinical levels for treatment of ADA-deficient severe combined immune deficiency subjects with suboptimal hematopoietic stem cell transplantation options.

Original languageEnglish (US)
Pages (from-to)1803-1816
Number of pages14
JournalMolecular Therapy
Volume22
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Vesicular Stomatitis
Adenosine Deaminase
Macaca mulatta
Severe Combined Immunodeficiency
Simian Immunodeficiency Virus
Glycoproteins
Viruses
Haplorhini
HIV-1
Gibbon ape leukemia virus
Genes
Lung
Blood Cell Count
Liver
Hematopoietic Stem Cell Transplantation
Therapeutics
Spleen
Complementary DNA
Bone Marrow
Phenotype

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer : Studies in infant ADA-Deficient mice and rhesus monkeys. / Sarracino, Denise Carbonaro; Tarantal, Alice F; Lee, Charles C; Martinez, Michele; Jin, Xiangyang; Wang, Xiaoyan; Hardee, Cinnamon L.; Geiger, Sabine; Kahl, Christoph A.; Kohn, Donald B.

In: Molecular Therapy, Vol. 22, No. 10, 01.01.2014, p. 1803-1816.

Research output: Contribution to journalArticle

Sarracino, Denise Carbonaro ; Tarantal, Alice F ; Lee, Charles C ; Martinez, Michele ; Jin, Xiangyang ; Wang, Xiaoyan ; Hardee, Cinnamon L. ; Geiger, Sabine ; Kahl, Christoph A. ; Kohn, Donald B. / Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer : Studies in infant ADA-Deficient mice and rhesus monkeys. In: Molecular Therapy. 2014 ; Vol. 22, No. 10. pp. 1803-1816.
@article{867edfd30b9d42e18a065bfd868ab0b5,
title = "Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: Studies in infant ADA-Deficient mice and rhesus monkeys",
abstract = "Systemic delivery of a lentiviral vector carrying a therapeutic gene represents a new treatment for monogenic disease. Previously, we have shown that transfer of the adenosine deaminase (ADA) cDNA in vivo rescues the lethal phenotype and reconstitutes immune function in ADA-deficient mice. In order to translate this approach to ADA-deficient severe combined immune deficiency patients, neonatal ADA-deficient mice and newborn rhesus monkeys were treated with species-matched and mismatched vectors and pseudotypes. We compared gene delivery by the HIV-1-based vector to murine γ-retroviral vectors pseudotyped with vesicular stomatitis virus-glycoprotein or murine retroviral envelopes in ADA-deficient mice. The vesicular stomatitis virus-glycoprotein pseudotyped lentiviral vectors had the highest titer and resulted in the highest vector copy number in multiple tissues, particularly liver and lung. In monkeys, HIV-1 or simian immunodeficiency virus vectors resulted in similar biodistribution in most tissues including bone marrow, spleen, liver, and lung. Simian immunodeficiency virus pseudotyped with the gibbon ape leukemia virus envelope produced 10- to 30-fold lower titers than the vesicular stomatitis virus-glycoprotein pseudotype, but had a similar tissue biodistribution and similar copy number in blood cells. The relative copy numbers achieved in mice and monkeys were similar when adjusted to the administered dose per kg. These results suggest that this approach can be scaled-up to clinical levels for treatment of ADA-deficient severe combined immune deficiency subjects with suboptimal hematopoietic stem cell transplantation options.",
author = "Sarracino, {Denise Carbonaro} and Tarantal, {Alice F} and Lee, {Charles C} and Michele Martinez and Xiangyang Jin and Xiaoyan Wang and Hardee, {Cinnamon L.} and Sabine Geiger and Kahl, {Christoph A.} and Kohn, {Donald B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/mt.2014.88",
language = "English (US)",
volume = "22",
pages = "1803--1816",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer

T2 - Studies in infant ADA-Deficient mice and rhesus monkeys

AU - Sarracino, Denise Carbonaro

AU - Tarantal, Alice F

AU - Lee, Charles C

AU - Martinez, Michele

AU - Jin, Xiangyang

AU - Wang, Xiaoyan

AU - Hardee, Cinnamon L.

AU - Geiger, Sabine

AU - Kahl, Christoph A.

AU - Kohn, Donald B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Systemic delivery of a lentiviral vector carrying a therapeutic gene represents a new treatment for monogenic disease. Previously, we have shown that transfer of the adenosine deaminase (ADA) cDNA in vivo rescues the lethal phenotype and reconstitutes immune function in ADA-deficient mice. In order to translate this approach to ADA-deficient severe combined immune deficiency patients, neonatal ADA-deficient mice and newborn rhesus monkeys were treated with species-matched and mismatched vectors and pseudotypes. We compared gene delivery by the HIV-1-based vector to murine γ-retroviral vectors pseudotyped with vesicular stomatitis virus-glycoprotein or murine retroviral envelopes in ADA-deficient mice. The vesicular stomatitis virus-glycoprotein pseudotyped lentiviral vectors had the highest titer and resulted in the highest vector copy number in multiple tissues, particularly liver and lung. In monkeys, HIV-1 or simian immunodeficiency virus vectors resulted in similar biodistribution in most tissues including bone marrow, spleen, liver, and lung. Simian immunodeficiency virus pseudotyped with the gibbon ape leukemia virus envelope produced 10- to 30-fold lower titers than the vesicular stomatitis virus-glycoprotein pseudotype, but had a similar tissue biodistribution and similar copy number in blood cells. The relative copy numbers achieved in mice and monkeys were similar when adjusted to the administered dose per kg. These results suggest that this approach can be scaled-up to clinical levels for treatment of ADA-deficient severe combined immune deficiency subjects with suboptimal hematopoietic stem cell transplantation options.

AB - Systemic delivery of a lentiviral vector carrying a therapeutic gene represents a new treatment for monogenic disease. Previously, we have shown that transfer of the adenosine deaminase (ADA) cDNA in vivo rescues the lethal phenotype and reconstitutes immune function in ADA-deficient mice. In order to translate this approach to ADA-deficient severe combined immune deficiency patients, neonatal ADA-deficient mice and newborn rhesus monkeys were treated with species-matched and mismatched vectors and pseudotypes. We compared gene delivery by the HIV-1-based vector to murine γ-retroviral vectors pseudotyped with vesicular stomatitis virus-glycoprotein or murine retroviral envelopes in ADA-deficient mice. The vesicular stomatitis virus-glycoprotein pseudotyped lentiviral vectors had the highest titer and resulted in the highest vector copy number in multiple tissues, particularly liver and lung. In monkeys, HIV-1 or simian immunodeficiency virus vectors resulted in similar biodistribution in most tissues including bone marrow, spleen, liver, and lung. Simian immunodeficiency virus pseudotyped with the gibbon ape leukemia virus envelope produced 10- to 30-fold lower titers than the vesicular stomatitis virus-glycoprotein pseudotype, but had a similar tissue biodistribution and similar copy number in blood cells. The relative copy numbers achieved in mice and monkeys were similar when adjusted to the administered dose per kg. These results suggest that this approach can be scaled-up to clinical levels for treatment of ADA-deficient severe combined immune deficiency subjects with suboptimal hematopoietic stem cell transplantation options.

UR - http://www.scopus.com/inward/record.url?scp=84926145124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926145124&partnerID=8YFLogxK

U2 - 10.1038/mt.2014.88

DO - 10.1038/mt.2014.88

M3 - Article

VL - 22

SP - 1803

EP - 1816

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 10

ER -